Gemini Therapeutics Announces ASCO 2026 Analyses Supporting Aldoxorubicin's Tumor-Targeted Delivery and Cardiac-Safety Profile

SAN FRANCISCO--(BUSINESS WIRE)-- #ASCO--Gemini Therapeutics Announces ASCO 2026 Analyses Supporting Aldoxorubicin's Tumor-Targeted Delivery and Cardiac-Safety Profile.